A Phase-1 Clinical Trial of a DNA Vaccine for Venezuelan Equine Encephalitis Delivered by Intramuscular or Intradermal Electroporation
Abstract
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne alphavirus, which causes periodic epizootics in equines and is a recognized biological defense threat for humans. There are currently no licensed vaccines against VEEV available in the United States. We developed a candidate DNA vaccine expressing the E3-E2-6K-E1 genes of VEEV (pWRG/VEEV) and performed a Phase 1 clinical trial to assess safety, reactogenicity, tolerability, and immunogenicity.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 25, 2016
- Accession Number
- AD1009502
Entities
People
- Barry Ellefsen
- Connie S Schmaljohn
- Drew Hannaman
- Lesley C. Dupuy
Organizations
- United States Army Medical Research Institute of Infectious Diseases